Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bexagliflozin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 known ✓ | P31639 | 20/20 | 1.00 |
| ▸ | SLC5A1 | P13866 | 16/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.76 |
| ▸ | SLC5A11 | Q8WWX8 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bexagliflozin SCHEMBL18058586 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Bexagliflozin SCHEMBL29456628 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Bexagliflozin SCHEMBL15324561 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Bexagliflozin SCHEMBL15324563 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Bexagliflozin SCHEMBL31364363 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Bexagliflozin SCHEMBL16421564 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Bexagliflozin SCHEMBL16510222 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Bexagliflozin SCHEMBL302200 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Bexagliflozin SCHEMBL22264462 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 | |
| Bexagliflozin SCHEMBL17929391 | 1.00 | SLC5A2 (1.00) | SLC5A2SLC5A1ADRA2ASLC5A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759474-B2 | Use of SGLT-2 inhibitors in the drying-off of non-human mammals | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-09-19 | — | — | US | disclosed |
| US-11759474-B2 | Use of SGLT-2 inhibitors in the drying-off of non-human mammals | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2023-09-19 | — | — | US | disclosed |
| EP-3938039-A1 | A COMPOUND FOR THE MANAGEMENT OF FELINE DIABETES | Increvet, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20210283100-A1 | ASCORBIC ACID, QUINONE COMPOUND, AND SODIUM GLUCOSE COTRANSPORTER INHIBITOR FOR TREATING CANCER | IC MEDTECH CORP (US) | 2021-09-16 | — | — | US | disclosed |
| WO-2020186142-A1 | A COMPOUND FOR THE MANAGEMENT OF FELINE DIABETES | INCREVET, INC. (US) | 2020-09-17 | — | — | WO | disclosed |
| WO-2018026673-A1 | ASCORBIC ACID, QUINONE COMPOUND, AND SODIUM GLUCOSE COTRANSPORTER INHIBITOR FOR TREATING CANCER | IC-MedTech Corp. (US) | 2018-02-08 | — | — | WO | disclosed |
| EP-2836500-A1 | PROCESS FOR PREPARATION OF BENZYLBENZENE SODIUM-DEPENDENT GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS | Theracos, Inc. (US) | 2015-02-18 | — | — | EP | disclosed |
| WO-2013152654-A1 | PROCESS FOR PREPARATION OF BENZYLBENZENE SODIUM-DEPENDENT GLUCOSE COTRANSPORTER 2 (SGLT2) INHIBITORS | THERACOS, INC. (US) | 2013-10-17 | — | — | WO | disclosed |
| EP-2580225-A1 | CRYSTALLINE FORM OF BENZYLBENZENE SGLT2 INHIBITOR | Theracos, Inc. (US) | 2013-04-17 | — | — | EP | disclosed |
| WO-2011153953-A1 | CRYSTALLINE FORM OF BENZYLBENZENE SGLT2 INHIBITOR | THERACOS, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
| WO-2011153712-A1 | CRYSTALLINE FORM OF BENZYLBENZENE SGLT2 INHIBITOR | THERACOS, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283100-A1 | ASCORBIC ACID, QUINONE COMPOUND, AND SODIUM GLUCOSE COTRANSPORTER INHIBITOR FOR TREATING CANCER | SLC5A1, SLC5A2, SLC5A6 | SLC5A2 2/4885SLC5A1 1/4885ADRA2A 1598/4885 |
| US-11759474-B2 | Use of SGLT-2 inhibitors in the drying-off of non-human mammals | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885ADRA2A 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.